Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
B. Riley Securities analyst William Woods initiates coverage on Immunic (NASDAQ:IMUX) with a Buy rating and announces Price ...
Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.23) by 8....
Piper Sandler analyst Yasmeen Rahimi reiterates Immunic (NASDAQ:IMUX) with a Overweight and maintains $28 price target.
The company also reported that Werner Gladdines, current Vice President, Program Management & Clinical Development Operatio...
https://www.sec.gov/Archives/edgar/data/1280776/000119380524000704/e663650_s3a-immunic.htm
Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.26) by ...
30 mg and 45 mg Daily Doses of Vidofludimus Calcium Suppressed Development of Gadolinium-Enhancing Lesions by 78% and 74% Com...
